Ashumi Gupta1, Shyama Jain2, Nita Khurana3, Arun Kumar Kakar4. 1. Assistant Professor, Department of Pathology, Baba Saheb Ambedkar Medical College and Hospital , New Delhi, India . 2. Professor and Head of the Department, Department of Pathology, Maulana Azad Medical College , New Delhi, India . 3. Professor, Department of Pathology, Maulana Azad Medical College , New Delhi, India . 4. Director Professor, Department of Surgery, Lok Nayak Hospital , New Delhi, India .
Abstract
INTRODUCTION: Bcl-2 is a marker recently studied in thyroid tumours and proposed to have prognostic significance. p63 is expressed in a proportion of papillary thyroid carcinoma cases and may have a role in tumour progression. AIM: To study expression of Bcl2 and p63 in thyroid tumours and correlation of Bcl-2 with diagnostic markers including Thyroglobulin, Calcitonin and Carcinoembryonic antigen. MATERIALS AND METHODS: Cytology smears of 35 cases of thyroid cancer were studied over a period of 18 months. In 20 cases histopathology was available. Immunocytochemistry for Bcl-2 and p63 was done, and diagnostic markers were applied as and when required. RESULTS: p63 showed focal nuclear expression in 46.1% of papillary thyroid carcinoma cases, and was negative in all other tumours. Bcl-2 was positive in 88.9% of follicular carcinomas, 100% of papillary carcinomas and 83.3% of medullary carcinoma cases, and showed focal weak expression in 40% of Anaplastic Carcinoma (ATC) cases, thereby signifying down regulation (p-value = 0.001). There was significant down regulation of Thyroglobulin (Tg) in ATC vs well differentiated follicular derived tumours (p-value ≤ 0.016). Positive correlation was noted between expression of Bcl-2 and Calcitonin (0.93) and Bcl-2 and Carcinoembryonic Antigen (CEA) (0.89), and weak positive correlation (0.65) between Tg and Bcl-2. CONCLUSION: Bcl-2 is downregulated in anaplastic carcinomas as compared to well differentiated thyroid tumours, and shows correlation with differentiation associated tumour antigens. Thus, loss of Bcl-2 was associated with loss of differentiation in thyroid tumours. Anaplastic carcinoma as such is associated with worse prognosis and loss of Bcl-2 may be partly responsible for the same. p63 is specific but less sensitive marker for PTC. Further studies are required to determine the role of Bcl-2 and p63 in thyroid tumours.
INTRODUCTION:Bcl-2 is a marker recently studied in thyroid tumours and proposed to have prognostic significance. p63 is expressed in a proportion of papillary thyroid carcinoma cases and may have a role in tumour progression. AIM: To study expression of Bcl2 and p63 in thyroid tumours and correlation of Bcl-2 with diagnostic markers including Thyroglobulin, Calcitonin and Carcinoembryonic antigen. MATERIALS AND METHODS: Cytology smears of 35 cases of thyroid cancer were studied over a period of 18 months. In 20 cases histopathology was available. Immunocytochemistry for Bcl-2 and p63 was done, and diagnostic markers were applied as and when required. RESULTS:p63 showed focal nuclear expression in 46.1% of papillary thyroid carcinoma cases, and was negative in all other tumours. Bcl-2 was positive in 88.9% of follicular carcinomas, 100% of papillary carcinomas and 83.3% of medullary carcinoma cases, and showed focal weak expression in 40% of Anaplastic Carcinoma (ATC) cases, thereby signifying down regulation (p-value = 0.001). There was significant down regulation of Thyroglobulin (Tg) in ATC vs well differentiated follicular derived tumours (p-value ≤ 0.016). Positive correlation was noted between expression of Bcl-2 and Calcitonin (0.93) and Bcl-2 and Carcinoembryonic Antigen (CEA) (0.89), and weak positive correlation (0.65) between Tg and Bcl-2. CONCLUSION:Bcl-2 is downregulated in anaplastic carcinomas as compared to well differentiated thyroid tumours, and shows correlation with differentiation associated tumour antigens. Thus, loss of Bcl-2 was associated with loss of differentiation in thyroid tumours. Anaplastic carcinoma as such is associated with worse prognosis and loss of Bcl-2 may be partly responsible for the same. p63 is specific but less sensitive marker for PTC. Further studies are required to determine the role of Bcl-2 and p63 in thyroid tumours.
Authors: F Branet; P Brousset; S Krajewski; D Schlaifer; J Selves; J C Reed; P Caron Journal: J Clin Endocrinol Metab Date: 1996-07 Impact factor: 5.958
Authors: Ana Preto; José Cameselle-Teijeiro; Julio Moldes-Boullosa; Paula Soares; Jorge F Cameselle-Teijeiro; Paula Silva; Jorge S Reis-Filho; Rosa M Reyes-Santías; Natividad Alfonsín-Barreiro; Jerónimo Forteza; Manuel Sobrinho-Simões Journal: Mod Pathol Date: 2004-07 Impact factor: 7.842
Authors: Afaf T Ibrahiem; Amin K Makhdoom; Khalid S Alanazi; Abdulaziz M Alanazi; Abdulaziz M Mukhlef; Saad H Elshafey; Eman A Toraih; Manal S Fawzy Journal: J Clin Lab Anal Date: 2022-04-07 Impact factor: 3.124